Actively Recruiting
French Assessment of Minimal Residual Disease by Liquid Biopsies in Pancreatic Ductal Adenocarcinoma Patients
Led by University Hospital, Montpellier · Updated on 2025-07-10
37
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, focusing on the use of circulating tumor DNA (ctDNA) as a marker to detect residual disease and predict the risk of cancer recurrence. This study aims to confirm that ctDNA detected after treatment, including surgery and chemotherapy, can identify patients with a high risk of recurrence and improve clinical practice. It is part of the larger European GUIDE.MRD project, developing international standards for ctDNA diagnostics. The study involves patients in France who undergo potentially curative surgery for PDAC. Blood samples will be collected repeatedly at specific times to analyze ctDNA levels. The study will also compare different commercial ctDNA tests to determine the most effective at various time points. The researchers will assess ctDNA levels before and after chemotherapy and explore the relationship between ctDNA detection and imaging results. Participants will be followed for up to three years after treatment, during which their blood samples, disease-free survival, time to clinical and molecular recurrence, and overall survival will be monitored. The study will also evaluate how ctDNA analysis correlates with CT scan findings and whether it can guide the timing of imaging. Patients' consent and compliance will be closely managed, and their health information will be securely stored for research.
CONDITIONS
Brief Title
French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with pancreatic ductal adenocarcinoma as assessed by the multidisciplinary tumor board
- Age 18 years or older
- Scheduled for surgery intended to cure the pancreatic cancer
You will not qualify if you...
- Hereditary pancreatic cancer
- Verified distant metastases
- Unlikely to comply with study protocol or complete study visits
- Other cancers (except prior pancreatic cancer or skin cancer other than melanoma) within 3 years
- Pregnant or nursing women, or women of childbearing age not using contraception
- Adults under legal protection
- Not covered by health insurance
- Unable to understand or sign informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment and informed consent
Duration - Surgery and immediate postoperative period
Participants undergo surgery intended to cure pancreatic ductal adenocarcinoma, followed by blood sampling for ctDNA analysis at predefined time points.
Blood samples collected at surgery and during standard-of-care CT scan visits
Duration - Up to 3 years after surgery
Participants have repeated blood sampling for ctDNA analysis during follow-up to monitor minimal residual disease and correlate with clinical outcomes.
Multiple blood sampling visits aligned with routine CT scans during follow-up
Trial Site Locations
Total: 1 location
1
CHU de Montpellier
Montpellier, Hérault, France, 34295
Actively Recruiting
Research Team
C
Catherine ALIX-PANABIERES, Ph.D
T
Thomas BARDOL, M.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here